Pharmaceutical companies including AstraZeneca and Boehringer Ingelheim, along with new entrants, have launched direct-to-patient prescription programs in the U.S. to improve medication access and affordability. AstraZeneca’s platform offers significant savings on chronic condition drugs, while Boehringer Ingelheim provides respiratory and diabetes medications at reduced prices. These initiatives coincide with drug pricing deals like Pfizer’s with the Trump administration, aiming to lower list prices and distribute medications through online platforms, reflecting a growing industry shift to patient-centric distribution models.